Methods and compositions for limiting the biodistribution of AAV

JP2023548976A5Inactive Publication Date: 2024-11-12AFFINIA THERAPEUTICS INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023552153
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-15
Filing Date
2021-11-09
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0074】 5.図面のいくつかの図の簡単な説明 本発明のこれらおよび他の特徴、態様、および利点は、以下の説明および添付の図面に関してよりよく理解される。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to an improved method of treating a patient with recombinant adeno-associated virus (rAAV) by adjunctively administering to the patient via systemic administration a composition comprising at least one antibody or antigen-binding fragment thereof capable of neutralizing non-systemically administered rAAV. The present disclosure further provides kits for combination therapy. The present disclosure relates to an improved method of treating a patient with rAAV by adjunctively administering to the patient via systemic administration a composition comprising an antibody or antigen-binding fragment thereof capable of neutralizing non-systemically administered rAAV.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] 1. Cross-reference of related applications This application claims the interests of U.S. Provisional Patent Application No. 63 / 111,496, filed on 9 November 2020, and U.S. Provisional Patent Application No. 63 / 256,437, filed on 15 October 2021, the disclosures thereof incorporated herein by reference in their entirety.

[0002] 2. Sequence Listing This application includes a sequence listing submitted via EFS-Web, which is incorporated herein by reference in its entirety. The ASCII copy of said sequence listing, created in XX / 2021, is named 47299WO_CRF_sequencelisting.txt and has a size of XXX bytes. [Background technology]

[0003] 3.Background Adeno-associated viruses (AAVs) have become an ideal vector system for in vivo gene therapy. The variety of recombinant AAVs (rAAVs) designed to deliver therapeutic nucleic acids is increasing and is being developed and tested in non-human primates and humans. Recently, the FDA approved the commercialization of two rAAV gene therapy products.

[0004] Although AAV vectors are safer and less inflammatory than other viruses, toxicity has occurred after administration of high doses of rAAV for gene therapy. Studies in non-human primates have observed acute onset of thrombocytopenia and hypertransaminasemia, as well as liver damage, while human clinical studies have observed liver dysfunction, rapid increases in liver enzymes, and thrombocytopenia. Recently, several deaths have been reported in clinical trials of rAAV gene therapy for the treatment of hereditary neuromuscular disorders.

[0005] Local administration of rAAV to a target tissue or organ has been used to improve targeting and reduce systemic toxicity, but complete localization is impossible, and some serotypes of AAV show transduction in tissues distal from the injection site, posing a risk of systemic toxicity.

[0006] Therefore, there is a need for a method to restrict the biodistribution of AAV to target tissues and organs after local or regional administration while reducing or eliminating transduction of non-target tissues and organs such as the systemic circulation and the liver. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM

[0007] 4. Summary The present disclosure relates to an improved method of treating a patient with rAAV by additionally administering to the patient, via systemic administration, a composition comprising an antibody or an antigen-binding fragment thereof having the ability to neutralize non-systemically administered rAAV.

[0008] The additionally administered neutralizing antibody can limit the biodistribution of rAAV to target tissues and organs by neutralizing AAV in non-target organs and tissues. This systemic administration of the additional neutralizing antibody reduces non-target transduction of non-systemically administered rAAV that escapes the target organs and tissues, reduces systemic toxicity, and reduces the systemic immune response that migrates to the target tissues and organs transduced by rAAV.

[0009] Aspects of the present disclosure include an improved method of treating a patient by non-systemic administration of recombinant adeno-associated virus (rAAV). This improvement includes additionally administering to the patient, by systemic administration, a composition comprising at least one antibody or an antigen-binding fragment thereof having the ability to neutralize non-systemically administered rAAV.

[0010] In some embodiments, at least one antibody or antigen-binding fragment binds to at least one capsid protein of rAAV. In some embodiments, the rAAV has a capsid protein of AAV selected from AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI.

[0011] In some embodiments, at least one antibody is an IgG antibody.

[0012] In some embodiments, the composition has the ability to neutralize rAAV selected from AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI.

[0013] In some embodiments, the composition includes a monoclonal antibody.

[0014] In some embodiments, the composition comprises a polyclonal antibody containing a mixture of monoclonal antibodies.

[0015] In some embodiments, the composition comprises polyclonal antibodies obtained from at least 100 donors. In some embodiments, the polyclonal antibodies are obtained from at least 500, at least 1,000, at least 5,000, or at least 10,000 donors.

[0016] In some embodiments, the composition is intravenous immunoglobulin (IVIG). In some embodiments, the IVIG is a pool of antibodies obtained from Gammagard® Liquid® (Baxter Healthcare Corporation), Gammagard® S / D, Gammaplex®, Bivigam®, Carimune® NF, Gamunex-C, Gammaked®, Flebogamma® DIF, Octagam®, and Privigen®.

[0017] In some embodiments, the composition comprises a recombinant polyclonal antibody. In some embodiments, the composition comprises recombinant IVIG (rIVIG).

[0018] In some embodiments, at least one antibody is an antigen-binding fragment selected from single-chain Fv(scFv), Fab, (Fab')2, and (scFv)2. In some embodiments, the composition includes a bispecific antibody, a single-domain antibody (dAb), a diabody (Db), a nanobody, and a unibody.

[0019] In some embodiments, the composition is administered by intravenous injection or infusion.

[0020] In some embodiments, the composition is IVIG, which is administered in doses ranging from 1 to 2000 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 2 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 10 mg / ml. In some embodiments, IVIG is administered in doses ranging from 1 to 4 mg / ml. In some embodiments, IVIG is administered as a single dose. In some embodiments, IVIG is administered daily.

[0021] In some embodiments, IVIG is administered twice, three times, or four times a day.

[0022] In some embodiments, IVIG is administered twice, three, or four times a day. In some embodiments, IVIG is administered over a period of one week or less.

[0023] In some embodiments, IVIG is administered for at least 5 minutes, at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 25 minutes, or at least 30 minutes.

[0024] In some embodiments, the composition is administered before administering rAAV to the patient. In some embodiments, the composition is administered at least 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 12 hours, or at least 24 hours before administering rAAV to the patient. In some embodiments, the composition is administered 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, or 24 hours before administering rAAV to the patient. In some embodiments, the composition is administered up to one week before administering rAAV to the patient.

[0025] In some embodiments, the composition is administered after the patient has been administered rAAV. In some embodiments, the composition is administered within 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 24 hours, or within 1 week after the patient has been administered rAAV.

[0026] In some embodiments, the composition is administered on the same day that rAAV is administered to the patient.

[0027] In some embodiments, the composition is administered in an amount sufficient to alter the distribution of rAAV in the body after administration to the patient.

[0028] In some embodiments, altering the distribution of rAAV in the body reduces infection of hepatocytes. In some embodiments, altering the distribution of rAAV in the body reduces infection of cells other than target sites.

[0029] In some embodiments, the composition is administered in an amount sufficient to reduce the hepatotoxicity of rAAV after administration to the patient. In some embodiments, the composition is administered in an amount sufficient to reduce the toxicity of rAAV outside the target site after administration to the patient.

[0030] In some embodiments, the composition is administered in an amount sufficient to neutralize the rAAV released from the target site.

[0031] In some embodiments, the target site is selected from the patient's brain, spinal cord, muscles, eyes, and ears. In some embodiments, the target site is not located within the patient's central nervous system.

[0032] Aspects of the present disclosure include a method for treating a patient, comprising the steps of: administering a first pharmaceutical composition comprising recombinant adeno-associated virus (rAAV) non-systemically to a target site in the patient; and administering a second pharmaceutical composition comprising at least one antibody having the ability to neutralize non-systemically administered rAAV to the patient adjunctally by systemic administration.

[0033] In some embodiments, at least one antibody binds to the capsid protein of rAAV. In some embodiments, rAAV is AAV2;AAV1;AAV6;AAV3;AAV LK03;AAV7;AAV8;AAV hu.37;AAV rh.10;AAV9;AAV hu.68;AAV10;AAV5;AAV3-3;AAV4-4;AAV1-A;hu.46-A;hu.48-A;hu.44-A;hu.43-A;AAV6-A;hu.34-B;hu.47-B;hu.29 -B;rh.63-B;hu.56-B;hu.45-B;rh.57-B;rh.35-B;rh.58-B;rh.28-B;rh.51-B;rh.19-B;rh.49-B;rh.52-B;rh.13-B; AAV2-B;rh.20-B;rh.24-B;rh.64-B;hu.27-B;hu.21-B;hu.22-B;hu.23-B;hu.7-C;hu.61-C;rh.56-C;hu.9-C;hu.54- C;hu.53-C;hu.60-C;hu.55-C;hu.2-C;hu.1-C;hu.18-C;hu.3-C;hu.25-C;hu.15-C;hu.16-C;hu.11-C;hu.10-C;hu.4 -C;rh.54-D;rh.48-D;rh.55-D;rh.62-D;AAV7-D;rh.52-E;rh.51-E;hu.39-E;rh.53-E;hu.37-E;rh.43-E;rh.50-E;r h.49-E;rh.61-E;hu.41-E;rh.64-E;hu.42-E;rh.57-E;rh.40-E;hu.67-E;hu.17-E;hu.6-E;hu.66-E;rh.38-E;hu.32 It has a capsid protein of AAV selected from -F;AAV9 / hu;hu.31-F;Anc80;Anc81;Anc82;Anc83;Anc84;Anc94;Anc113;Anc126;Anc127;Anc80L27;Anc80L59;Anc80L60;Anc80L62;Anc80L65;Anc80L33;Anc80L36;Anc80L44;Anc80L1;Anc110; and Anc80DI. In some embodiments, AAV is AAV8 or AAV9. In some embodiments, AAV is rh.10.In some embodiments, AAV is hu.68.

[0034] In some embodiments, the antibody is an IgG antibody.

[0035] AAV2;AAV1;AAV6;AAV3;AAVLK03;AAV7;AAV38;AAV37;AAV103;AAV7;AAV38;AAV37; hu.68;AAV10;AAV5;AAV3-3;AAV4-4;AAV1-A;hu.46-A;hu.48-A;hu.44-A;hu.43-A;AAV6-A;hu.34-B;hu.47-B;hu.29 -B;rh.63-B;hu.56-B;hu.45-B;rh.57-B;rh.35-B;rh.58-B;rh.28-B;rh.51-B;rh.19-B;rh.49-B;rh.52-B;rh.13-B;rh. ;AAV2-B;rh.20-B;rh.24-B;rh.64-B;hu.27-B;hu.21-B;hu.22-B;hu.23-B;hu.7-C;hu.61-C;rh.56-C;hu.9-C;hu.5 4-C;hu.53-C;hu.60-C;hu.55-C;hu.2-C;hu.1-C;hu.18-C;hu.3-C;hu.25-C;hu.15-C;hu.16-C;hu.11-C;hu.15-C;hu.16-C;hu.11-C;hu.10-C;hu. .4-C;rh.54-D;rh.48-D;rh.55-D;rh.62-D;AAV7-D;rh.52-E;rh.51-E;hu.39-E;rh.53-E;hu.37-E;rh.43-E;rh.50-E;rh. E;rh.49-E;rh.61-E;hu.42-E;rh.57-E;rh.40-E;hu.67-E;hu.17-E;hu.6-E;hu.66-E;rh.38-E;hu .32-F;AAV9 / hu;hu.31-F;Anc80;Anc81;Anc82;Anc83;Anc84;Anc94;Anc113;Anc126;Anc127;Anc80L27;Anc80L59;A nc80L60;Anc80L62;Anc80L65;Anc80L33;Anc80L36;Anc80 L44;Anc80L1;Anc110;およびAnc80DIか?

[0036] In some embodiments, at least one antibody is a monoclonal antibody. In some embodiments, the second pharmaceutical composition comprises a polyclonal antibody comprising a mixture of monoclonal antibodies.

[0037] In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 100 donors. In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 500, 1,000, 5,000, or 10,000 donors.

[0038] In some embodiments, the second pharmaceutical composition comprises intravenous immunoglobulin (IVIG). In some embodiments, the IVIG is a pool of antibodies obtained from Gammagard® Liquid® (Baxter Healthcare Corporation), Gammagard® S / D, Gammaplex®, Bivigam®, Carimune® NF, Gamunex-C, Gammaked®, Flebogamma® DIF, Octagam®, and Privigen®.

[0039] In some embodiments, the second pharmaceutical composition includes a recombinant polyclonal antibody.

[0040] In some embodiments, the second pharmaceutical composition comprises recombinant IVIG (rIVIG). In some embodiments, at least one antibody comprises an antigen-binding fragment selected from single-chain Fv (scFv), Fab, (Fab')2, and (scFv)2.

[0041] In some embodiments, at least one antibody includes a bispecific antibody, a single-domain antibody (dAb), a diabody (Db), a nanobody, a unibody, and a diabody.

[0042] In some embodiments, the first pharmaceutical composition is administered topically.

[0043] In some embodiments, the target site is located within the central nervous system. In some embodiments, the target site is selected from the patient's brain, spinal cord, muscles, eyes, and ears.

[0044] In some embodiments, the first pharmaceutical composition is administered by intrathecal injection or infusion, intraocular injection, intravitreous injection or infusion, inner ear injection or infusion, intraventricular injection or infusion, intracisional injection or infusion, subretinal injection or infusion, or intramuscular injection or infusion. In some embodiments, intrathecal injection or infusion is lumbar injection or infusion. In some embodiments, the first pharmaceutical composition is administered to the brain or spinal cord by intracerebral, intrathecal, intracranial, intraventricular, or cisternal injection.

[0045] In some embodiments, the second pharmaceutical composition is administered systemically. In some embodiments, the second pharmaceutical composition is administered by intravenous injection or infusion.

[0046] In some embodiments, the second pharmaceutical composition comprises IVIG, which is administered in doses ranging from 1 to 2000 mg / kg.

[0047] In some embodiments, IVIG is administered in doses ranging from 1 to 2 mg / kg. In some embodiments, IVIG is administered in doses ranging from 1 to 10 mg / ml. In some embodiments, IVIG is administered in doses ranging from 1 to 4 mg / ml. In some embodiments, IVIG is administered as a single dose.

[0048] In some embodiments, IVIG is administered daily. In some embodiments, IVIG is administered at least twice a day.

[0049] In some embodiments, the second pharmaceutical composition is administered to the patient before the first pharmaceutical composition is administered.

[0050] In some embodiments, the second pharmaceutical composition is administered at least 30 minutes, at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, or at least 24 hours before administering the first pharmaceutical composition to the patient.

[0051] In some embodiments, the second pharmaceutical composition is administered at least one day, at least one week, or at least two weeks before administering the first pharmaceutical composition to the patient.

[0052] In some embodiments, the second pharmaceutical composition is administered to the patient after the first pharmaceutical composition has been administered.

[0053] In some embodiments, the second pharmaceutical composition is administered at least 30 minutes, at least 1 hour, or at least 2 hours after the administration of the first pharmaceutical composition to the patient.

[0054] In some embodiments, the second pharmaceutical composition is administered at least one day, at least two days, or at least one week after the administration of the first pharmaceutical composition to the patient.

[0055] In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are administered on the same day.

[0056] In some embodiments, the second pharmaceutical composition is administered in an amount sufficient to alter the in vivo distribution of rAAV after administration to the patient.

[0057] In some embodiments, altering the distribution of AAV in the body reduces rAAV infection in hepatocytes. In some embodiments, altering the distribution of AAV in the body reduces rAAV infection in cells other than target sites.

[0058] In some embodiments, the second pharmaceutical composition is administered to the patient in an amount sufficient to reduce the hepatotoxicity of rAAV after administration.

[0059] In some embodiments, the second pharmaceutical composition is administered to the patient in an amount sufficient to reduce the toxicity of rAAV outside the target site after administration.

[0060] In some embodiments, the target site is selected from the patient's brain, spinal cord, muscles, eyes, and ears.

[0061] In some embodiments, the target site is not located within the central nervous system.

[0062] Aspects of this disclosure include a kit for combination therapy comprising a first pharmaceutical composition comprising recombinant adeno-associated virus (rAAV) and a second pharmaceutical composition comprising at least one antibody having the ability to neutralize the rAAV of the first pharmaceutical composition when administered non-systemically.

[0063] In some embodiments, at least one antibody binds to the rAAV capsid protein. In some embodiments, the AAV capsid proteins are AAV2;AAV1;AAV6;AAV3;AAV LK03;AAV7;AAV8;AAV hu.37;AAV rh.10;AAV9;AAV hu.68;AAV10;AAV5;AAV3-3;AAV4-4;AAV1-A;hu.46-A;hu.48-A;hu.44-A;hu.43-A;AAV6-A;hu.34-B;hu.47-B;hu. 29-B;rh.63-B;hu.56-B;hu.45-B;rh.57-B;rh.35-B;rh.58-B;rh.28-B;rh.51-B;rh.19-B;rh.49-B;rh.52-B;rh.1 3-B;AAV2-B;rh.20-B;rh.24-B;rh.64-B;hu.27-B;hu.21-B;hu.22-B;hu.23-B;hu.7-C;hu.61-C;rh.56-C;hu.9-C; hu.54-C;hu.53-C;hu.60-C;hu.55-C;hu.2-C;hu.1-C;hu.18-C;hu.3-C;hu.25-C;hu.15-C;hu.16-C;hu.11-C;hu.1 0-C;hu.4-C;rh.54-D;rh.48-D;rh.55-D;rh.62-D;AAV7-D;rh.52-E;rh.51-E;hu.39-E;rh.53-E;hu.37-E;rh.43- E;rh.50-E;rh.49-E;rh.61-E;hu.41-E;rh.64-E;hu.42-E;rh.57-E;rh.40-E;hu.67-E;hu.17-E;hu.6-E;hu.66-E; Selected from rh.38-E;hu.32-F;AAV9 / hu;hu.31-F;Anc80;Anc81;Anc82;Anc83;Anc84;Anc94;Anc113;Anc126;Anc127;Anc80L27;Anc80L59;Anc80L60;Anc80L62;Anc80L65;Anc80L33;Anc80L36;Anc80L44;Anc80L1;Anc110; and Anc80DI.

[0064] In some embodiments, at least one antibody comprises IgG.

[0065] In some embodiments, the second pharmaceutical composition has the ability to neutralize AAV selected from AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI.

[0066] In some embodiments, at least one antibody is a monoclonal antibody.

[0067] In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 100 donors. In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 500, 1,000, 5,000, or 10,000 donors.

[0068] In some embodiments, the second pharmaceutical composition comprises intravenous immunoglobulin (IVIG).

[0069] In some embodiments, the second pharmaceutical composition comprises recombinant intravenous immunoglobulin (rIVIG).

[0070] In some embodiments, IVIG is a pool of antibodies obtained from Gammagard® Liquid® (Baxter Healthcare Corporation), Gammagard® S / D, Gammaplex®, Bivigam®, Carimune® NF, Gamunex-C, Gammaked®, Flebogamma® DIF, Octagam®, and Privigen®.

[0071] In some embodiments, the second pharmaceutical composition includes a recombinant polyclonal antibody.

[0072] In some embodiments, the second pharmaceutical composition comprises an AAV neutralizing antigen-binding fragment selected from single-chain Fv(scFv), Fab, (Fab')2, and (scFv)2.

[0073] In some embodiments, the second pharmaceutical composition includes a bispecific antibody, a single-domain antibody (dAb), a diabody (Db), a nanobody, a unibody, and a diabody.

[0074] 5. Brief explanation of some of the figures in the drawing These and other features, aspects, and advantages of the present invention will be better understood with reference to the following description and accompanying drawings. [Brief explanation of the drawing]

[0075] [Figure 1-1] Figures 1A–1G show the in vivo distribution of vector genome copies in various tissues of mice treated with AAV9.CAG.GFP, with or without IVIG administration, as measured by ddPCR. The Y-axis represents the ratio of eGFP DNA copy number to RPP30 DNA copy number, and the x-axis represents the treatment condition. Each graph shows eGFP expression in the brain (Figure 1A), liver (Figure 1B), spleen (Figure 1C), cervical DRG (Figure 1D), lumbar DRG (Figure 1E), heart (Figure 1F), or kidney (Figure 1G). Data points represent individual animals, and lines represent the mean. Statistics were performed using one-way ANOVA and Tukey's multiple comparison test. [Figure 1-2] Same as above. [Figure 1-3] Same as above. [Figure 1-4] Same as above.

[0076] [Figure 2-1] Figures 2A–2G show eGFP mRNA expression in various tissues of mice treated with AAV9.CAG.GFP, with or without IVIG administration, as measured by RT-ddPCR. The Y-axis represents the ratio of eGFP transcript to RPP30 transcript, and the x-axis represents the treatment condition. Each graph shows eGFP expression in the brain (Figure 2A), liver (Figure 2B), spleen (Figure 2C), cervical / thoracic DRG (Figure 2D), lumbar DRG (Figure 2E), heart (Figure 2F), or kidney (Figure 2G). Data points represent individual animals, and lines represent the mean. Statistics were performed using one-way ANOVA and Tukey's multiple comparison test. [Figure 2-2] Same as above. [Figure 2-3] Same as above. [Figure 2-4] Same as above.

[0077] [Figure 3A]Figures 3A–3G show anti-GFP immunohistochemical data in various tissues of mice treated with AAV9.CAG.GFP, with or without IVIG treatment. Anti-GFP immunohistochemistry was performed on sections of the brain (Figure 3A), liver (Figure 3B), spleen (Figure 3C), cervical / thoracic DRG (Figure 3D), lumbar DRG (Figure 3E), heart (Figure 3F), or kidney (Figure 3G) of animals transduced with saline; AAV9.CAG.GFP ICV; AAV9.CAG.GFP ICV with 2 hours of IVIG; AAV9.CAG.GFP with 24 hours of IVIG; or AAV9.CAG.GFP IV. GFP-positive cells are stained brown (shown as dark gray cells in Figures 3A–3G). DR - dorsal root. DRG - dorsal root ganglion. [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 3D] Same as above. [Figure 3E] Same as above. [Figure 3F] Same as above. [Figure 3G] Same as above. [Modes for carrying out the invention]

[0078] 6. Detailed explanation 6.1.Definition Unless otherwise defined, all technical and scientific terms used herein have the meanings generally understood by those skilled in the art to which this invention pertains. Where used herein, the following terms have the meanings set forth below.

[0079] As used herein, the term “rAAV” refers to a virion containing a recombinant nucleic acid construct encapsulated in an AAV capsid. The recombinant construct contains a polynucleotide payload located between the AAV reverse-terminal repeat sequences. The payload may be an expressible polynucleotide encoding a protein (e.g., a therapeutic protein) or a miRNA, siRNA, or guide RNA for a gene editing mechanism such as CRISPR. The payload may be a DNA homology construct for homologous recombination repair facilitated by gene editing.

[0080] As used herein, the terms “neutralize” or “neutralize” refer to a measurable reduction in the toxicity and / or circulating levels of AAV. The term “neutralizing antibody” refers to an antibody that has the ability to reduce the toxicity and / or circulating levels of AAV. Neutralizing antibodies can bind to the virus in ways such as blocking infection, blocking interaction with receptors, inhibiting genomic shedding, agglutinating the virus, inducing structural changes in the capsid, and preventing viral disassembly and shedding (the steps necessary for releasing DNA). Some neutralizing antibodies possess several of these effects.

[0081] The term “antibody” (which is also interchangeable with “immunoglobulin”) encompasses polyclonal, monoclonal, and allogeneic antibody preparations, which may be any of the classes of interest (e.g., IgM, IgG, IgA, and their subclasses), as well as preparations including hybrid antibodies, modified antibodies, F(ab')2 fragments, F(ab) molecules, Fv fragments, single-chain variable region fragments (scFv) presented on phages, nanobodies, single-chain antibodies, single-domain antibodies, chimeric antibodies, humanized antibodies, and functional fragments thereof that exhibit immunological binding properties to parent antibody molecules. Antibodies may be conjugated to other parts and / or bound to a support (e.g., a solid support) such as a polystyrene plate or beads or a test strip.

[0082] The antibodies and fragments of this disclosure include those that are bispecific or multispecific. A bispecific or multispecific antibody useful in the methods described herein may have binding specificity to at least two different epitopes, at least one of which is an rAAV epitope. The rAAV-binding antibodies and fragments may also be heteroantibodies. A heteroantibody is two or more antibodies or antibody-binding fragments (e.g., Fab) linked together, where each antibody or fragment has a different specificity.

[0083] When referring to antibodies, the phrases "bound to," "specifically bind to," or "specifically immunoreactive to" refer to a binding reaction that determines the presence of a protein in the presence of a heterogeneous population of proteins and other biologics. Therefore, under specified immunoassay conditions, a specified antibody will bind to a specific protein and not to other proteins present in the sample in significant amounts. Specific binding to a protein or virion under such conditions may require an antibody selected for its specificity to a particular protein. For example, an AAV neutralizing antibody can be produced against AAV7, specifically binding to the AAV7 virion and not to other virions present in tissues, organs, or body fluids. Various immunoassay formats can be used to select antibodies that are specifically immunoreactive to a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies that are specifically immunoreactive to a protein.

[0084] As used herein, the term “in vivo distribution” refers to the spread of AAV after administration, as well as its localization and persistence in tissues, fluids, or organs. For example, the in vivo distribution of AAV may include the amount of vector uptake and transduction into cells of the liver or other organs, as well as the expression of expressible polynucleotides, such as transgenes, RNA, or DNA-expressing polynucleotides. In some embodiments, the analysis of in vivo distribution may include, but is not limited to, quantification of viral genome expression by qPCR and deep sequencing, as well as AAV infection.

[0085] As used herein, the term “AAV capsid protein” refers to the naturally occurring VP1, VP2, or VP3 capsid proteins of the AAV serotypes, or to the non-naturally occurring VP1, VP2, or VP3 capsid proteins available or known in the art.

[0086] The term "adjunctive administration" or "administering adjunctively" refers to administering one therapeutic agent in close proximity to another therapeutic agent in time to provide an effect. Adjunctive administration may include administering one therapeutic agent simultaneously with the administration of the other therapeutic agent, sequentially (at different times but on the same day, for example, during the same patient's visit), or separately (on different days).

[0087] As used herein, the terms “IVIG” or “intravenous immunoglobulin” have the meanings commonly understood in the clinical field. IVIG contains a diverse, concentrated collection of antibodies against many antigens. IVIG is typically administered intravenously to the subject, but can be administered via different routes.

[0088] As used herein, the term “polyclonal antibody” typically refers to a population of heterologous antibodies produced by different B cell clones. They can recognize and bind to a single antigen or many different epitopes of many antigens. Polyclonal antibodies can be monospecific or polyspecific. Polyclonal antibodies may also be mixtures of monoclonal antibodies, though not limited to these.

[0089] As used herein, the term “recombinant polyclonal antibody” refers to a collection of heterologous antibodies produced by a library of recombinant constructs, each recombinant construct containing a coding sequence for an antibody or antigen-binding fragment. Recombinant polyclonal antibodies can recognize and bind to many different epitopes of a single antigen. In some embodiments, recombinant polyclonal antibodies recognize and bind to many different antigens.

[0090] As used herein, the term “target site” refers to the cell, tissue, organ, or body part to which the composition is administered.

[0091] Throughout this specification and the claims, “composition” and “pharmaceutical composition” are used interchangeably.

[0092] Throughout this specification and the claims, the word “comprise” or variations such as “comprises” or “comprising” is understood to mean that it includes the integer or set of integers described, but does not exclude any other integer or set of integers.

[0093] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described and is therefore naturally subject to change. Furthermore, since the scope of the present invention is limited only by the appended claims, it should also be understood that the terms used herein are intended solely to describe specific embodiments and are not intended to limit them.

[0094] Where a range of values ​​is provided, unless otherwise clearly stated in the context, each intermediate value between the upper and lower limits of that range, up to one-tenth of the lower limit unit, and any other stated values ​​or intermediate values ​​within that stated range are understood to be included within the invention. The upper and lower limits of these smaller ranges may independently be included within smaller ranges and are similarly included within the invention according to any specifically excluded limits within the stated range. If a stated range includes one or both limits, the range excluding one or both of those limits is also included within the invention.

[0095] Similar or equivalent methods and materials may be used in the practice or testing of the Method and Composition of Matter described herein, but suitable methods and materials are listed below. Furthermore, the materials, methods, and examples are illustrative and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated in full by reference.

[0096] It should be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” refer to multiple objects unless otherwise clearly indicated by the context. For example, a reference to “antibody or antigen-binding fragment” includes multiple such antibodies and antigen-binding fragments, and a reference to “recombinant adeno-associated virus” includes one or more recombinant adeno-associated viruses and their equivalents known to those skilled in the art. It should be further noted that the claims may be drafted to exclude any arbitrary element. Therefore, this statement is intended to act as an antecedent when using exclusive terms such as “exclusively,” “only,” or “negative” limitations in relation to the enumeration of elements of the claims.

[0097] It is understood that certain features of the Invention described in the context of separate embodiments for clarity may be provided in combination in a single embodiment. Conversely, various features of the Invention described in the context of a single embodiment for brevity may be provided individually or in any suitable subcombination. All combinations of embodiments relating to the Invention are specifically encompassed by the Invention and are disclosed herein as if any combination were individually expressly disclosed. Furthermore, all subcombinations of various embodiments and their elements are also specifically encompassed by the Invention and are disclosed herein as if any such subcombination were individually expressly disclosed herein.

[0098] The publications discussed herein are provided solely for their disclosure prior to the filing date of this application. Nothing herein should be construed as acknowledging that the present invention has no prior rights to such publications by prior art. Furthermore, the provided publication dates may differ from the actual publication dates and may need to be independently verified. 6.2. Other Interpretation Rules

[0099] The ranges listed herein are understood to be abbreviated notations of all values ​​within the range, including the listed endpoints. For example, the range from 1 to 50 is understood to include any number, combination of numbers, or subrange of the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50. 6.3. Treatment Method

[0100] In a first aspect, the disclosure provides an improved method for treating a patient with non-systemic administration of recombinant adeno-associated virus (rAAV). This improvement involves systemically administering to the patient an adjunctive composition comprising at least one antibody or antigen-binding fragment thereof having the ability to neutralize non-systemically administered rAAV.

[0101] Antibodies or their antigen-binding fragments can neutralize non-systemically administered rAAVs, particularly rAAVs that leave the administration site and enter systemic compartments. Systemic compartments in a patient may include, but are not limited to, non-target organs or tissues, or locations within the patient's circulatory system other than the target site.

[0102] Adjunctively administered antibody compositions reduce or eliminate tissue transduction by rAAVs that escape the administration site and enter systemic circulation. In particular, systemic administration of antibodies or antigen-binding fragments reduces non-target (e.g., liver) transduction by systemically circulating rAAVs in the patient, thereby reducing or eliminating toxicity (e.g., hepatotoxicity). Adjunctively administered antibody compositions can also reduce or eliminate the induction of a systemic immune response to rAAVs.

[0103] Another aspect of the present disclosure provides a method for treating a patient. The method comprises the steps of: administering a first pharmaceutical composition comprising recombinant adeno-associated virus (rAAV) to a patient non-systemically; and administering a second pharmaceutical composition comprising at least one antibody or antigen-binding fragment thereof having the ability to neutralize non-systemically administered rAAV to the patient adjunctally by systemic administration.

[0104] In some embodiments, the patient has not been treated with a treatment including rAAV prior to being treated with the method described herein. In some embodiments, the patient has been treated with a treatment including rAAV prior to being treated with the method described herein. 6.3.1. Recombinant adeno-associated virus (rAAV)

[0105] In the methods described herein, the first composition comprising recombinant AAV (rAAV) is administered non-systemically.

[0106] In some embodiments, the payload of the rAAV recombinant nucleic acid construct is an expressible polynucleotide. In certain embodiments, the expressible polynucleotide encodes a protein (e.g., a therapeutic protein). In certain embodiments, the expressible polynucleotide can be transcribed to provide a guide RNA, transactivated CRISPR RNA (tracrRNA), messenger RNA (mRNA), microRNA (miRNA), or shRNA.

[0107] In some embodiments, the payload provides a DNA homology construct for homologous recombination repair.

[0108] In some embodiments, rAAV is Zolgensma, Luxturna, other rAAV drugs developed for therapeutic purposes, or a variant thereof.

[0109] In some embodiments, rAAV comprises naturally occurring AAV serotype VP1, VP2, and / or VP3 capsid proteins. In some embodiments, rAAV comprises naturally occurring non-natural VP1, VP2, and / or VP3 capsid proteins. In certain embodiments of these embodiments, the naturally occurring non-natural VP1, VP2, and / or VP3 capsid proteins have a primary amino acid sequence different from that of naturally occurring capsids. In certain embodiments, the naturally occurring non-natural capsids include biological or chemical alterations or variant forms of naturally occurring AAV capsid proteins, in addition to or in addition to changes in the primary amino acid sequence.

[0110] In various embodiments, the capsid protein is a naturally occurring AAV serotype capsid protein of AAV1, AAV2, AAV3B, AAV5, AAV6, AAV8, or AAV9. In various embodiments, the capsid protein is selected from the capsid proteins disclosed in PCT / US2014 / 060163, USP9695220, PCT / US2016 / 044819, PCT / US2018 / 032166, PCT / US2019 / 031851, and PCT / US2019 / 047546, which are incorporated in their entirety herein by reference.

[0111] In some embodiments, the capsid protein is AAV9 (Genbank acceptance number: AAS99264.1), AAV1 (Genbank acceptance number: AAD27757.1), AAV2 (Genbank acceptance number: AAC03780.1), AAV3 (Genbank acceptance number: AAC55049.1), AAV3b (Genbank acceptance number: AF028705.1), AAV4 (Genbank acceptance number: AAC58045.1), AAV5 (Genbank acceptance number: AAD13756.1), AAV6 (Genbank acceptance number: AF028704.1), AAV7 (Genbank acceptance number: AAN03855.1), AAV These are capsid proteins of AAV8 (Genbank acceptance number: AAN03857.1), AAV10 (Genbank acceptance number: AAT46337.1), AAVrh10 (Genbank acceptance number: AY243015.1), AAV11 (Genbank acceptance number: AAT46339.1), AAV12 (Genbank acceptance number: ABI16639.1), AAV13 (Genbank acceptance number: ABZ10812.1), or AAVpol (Genbank acceptance number: FJ688147.1).

[0112] In various embodiments, the AAV capsid protein is a VP1, VP2, or VP3 capsid protein of AAV selected from the group consisting of: AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; and hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI, or variants thereof.

[0113] In some embodiments, the capsid protein is sequence number 54 (AAV1 (AAD27757)), sequence number 55 (AAV2 (AAC03780)), sequence number 56 (AAV3 (AAC55049)), sequence number 57 (AAV5 (AAD13756)), sequence number 58 (AAV6 (AAB95450)), sequence number 59 (AAV7 (AF513851_2)), sequence number 60 (AAV8 (AF513852_2)), sequence number 61 (AAV9 (AAS99264)), sequence number 62 (AAV10 (AAT46337)), sequence number 63 (AAV hu.68), sequence number 64 (AAV LK03), sequence number 65 (AAV hu.1 (AAS99260)), sequence number 66 (AAV hu.2(AAS99270)), SEQ ID NO: 67(AAV hu.3(AAS99280)), SEQ ID NO: 68(AAV hu.4(AAS99287)), SEQ ID NO: 69(AAV hu.6(AAS99306)), SEQ ID NO: 70(AAV hu.7(AAS99313)), SEQ ID NO: 71(AAV hu.9(AAS99314)), SEQ ID NO: 72(AAV hu.10(AAS99261)), SEQ ID NO: 73(AAV hu.11(AAS99262)), SEQ ID NO: 74(AAV hu.15(AAS99265)), SEQ ID NO: 75(AAV hu.16(AAS99266)), SEQ ID NO: 76(AAV hu.17(AAS99267)), SEQ ID NO: 77(AAV hu.18(AAS99268)), SEQ ID NO: 78(AAV hu.20(AAS99271)), SEQ ID NO: 79(AAV hu.21(AAS99272)), SEQ ID NO: 80(AAV hu.22(AAS99273)), SEQ ID NO: 81(AAV hu.23(AAS99274)), SEQ ID NO: 82(AAV hu.25(AAS99276)), SEQ ID NO: 83(AAV hu.27(AAS99277)), SEQ ID NO: 84(AAV hu.28(AAS99278)), SEQ ID NO: 85(AAV hu.29(AAS99279)), SEQ ID NO: 86(AAV hu.31(AAS99281)), SEQ ID NO: 87(AAV hu.32(AAS99282)), SEQ ID NO: 88(AAV hu.34(AAS99283)), Sequence ID 89(AAVhu.37(AAS99285)), Sequence ID 90(AAV hu.39 (AAS99286)), SEQ ID NO: 91 (AAV hu.41 (AAS99289)), SEQ ID NO: 92 (AAV hu.42 (AAS99290)), SEQ ID NO: 93 (AAV hu.43 (AAS99291)), SEQ ID NO: 94 (AAV hu.44 (AAS99292)), SEQ ID NO: 95 (AAV hu.45 (AAS99293)), SEQ ID NO: 96 (AAV hu.46 (AAS99294)), SEQ ID NO: 97 (AAV hu.47 (AAS99295)), SEQ ID NO: 98 (AAV hu.48 (AAS99296)), SEQ ID NO: 99 (AAV hu.51 (AAS99298)), SEQ ID NO: 100 (AAV hu.52 (AAS99299)), SEQ ID NO: 101 (AAV hu.53(AAS99300)), SEQ ID NO: 102(AAV hu.54(AAS99301)), SEQ ID NO: 103(AAV hu.55(AAS99302)), SEQ ID NO: 104(AAV hu.56(AAS99303)), SEQ ID NO: 105(AAV hu.57(AAS99304)), SEQ ID NO: 106(AAV hu.60(AAS99307)), SEQ ID NO: 107(AAV hu.61(AAS99308)), SEQ ID NO: 108(AAV hu.63(AAS99309)), SEQ ID NO: 109(AAV hu.66(AAS99311)), SEQ ID NO: 110(AAV hu.67(AAS99312)), SEQ ID NO: 111(AAV rh.10(AAO88201)), SEQ ID NO: 112(AAV rh.13(AAO88199)), SEQ ID NO: 113(AAV rh.19(AAO88194)), SEQ ID NO: 114(AAV rh.22(AAO88192)), SEQ ID NO: 115(AAV rh.23(AAO88191)), SEQ ID NO: 116(AAV rh.24(AAO88190)), SEQ ID NO: 117(AAV rh.35(AAO88186)), SEQ ID NO: 118(AAV rh.43(AAS99245)), SEQ ID NO: 119(AAV rh.48(AAS99246)), SEQ ID NO: 120(AAV rh.49(AAS99247)), SEQ ID NO: 121(AAV rh.50 (AAS99248), SEQ ID NO: 122 (AAV rh.51 (AAS99249)), SEQ ID NO: 123 (AAV rh.52 (AAS99250)), SEQ ID NO: 124 (AAV rh.53 (AAS99251)), SEQ ID NO: 125 (AAV rh.54 (AAS99252)), SEQ ID NO: 126 (AAV rh.55 (AAS99253)), SEQ ID NO: 127 (AAV rh.57 (AAS99254)), SEQ ID NO: 128 (AAV rh.58 (AAS99255)), SEQ ID NO: 129 (AAV rh.62 (AAS99258)), SEQ ID NO: 130 (AAV rh.64 (AAS99259)), SEQ ID NO: 131 (AAV This is a vp1 capsid protein having a sequence selected from rh.56 (JA400164), SEQ ID NO: 143 (Anc80L1), SEQ ID NO: 144 (Anc80L27), SEQ ID NO: 145 (Anc80L33), SEQ ID NO: 146 (Anc80L36), SEQ ID NO: 147 (Anc80L44), SEQ ID NO: 148 (Anc80L59), SEQ ID NO: 149 (Anc80L60), SEQ ID NO: 150 (Anc80L62), SEQ ID NO: 151 (Anc82DI), and SEQ ID NO: 152 (AAV rh.74).

[0114] In some embodiments, the protein is a vp1 capsid protein having a sequence selected from SEQ ID NO: 132 (Anc80), SEQ ID NO: 133 (Anc81 (AKU89596)), SEQ ID NO: 134 (Anc82 (AKU89597)), SEQ ID NO: 135 (Anc83 (AKU89598)), SEQ ID NO: 136 (Anc84 (AKU89599)), SEQ ID NO: 137 (Anc94), SEQ ID NO: 138 (Anc110 (AKU89600)), SEQ ID NO: 139 (Anc113 (AKU89601)), SEQ ID NO: 140 (Anc126 (AKU89602)), SEQ ID NO: 141 (Anc127 (AKU89603)), and SEQ ID NO: 142 (Anc80L65 (AKU89595)).

[0115] The AAV capsid protein may be a vp2 or vp3 protein having a part of one of the vp1 sequences. For example, the vp2 protein can have a sequence corresponding to amino acids 138 to 736 of AAV9 vp1, and the vp3 protein can have a sequence corresponding to amino acids 138 to 736 for the AAV9 vp1 protein. When a sequence number of a library sequence is used in the present disclosure, it refers to the sequence of any one member of the library. In some embodiments, the AAV capsid protein is a variant of the vp1, vp2, or vp3 protein described herein.

[0116] In some embodiments, rAAV is administered in a first composition. The first pharmaceutical composition comprises a therapeutically effective amount of rAAV and a physiologically compatible carrier. Suitable carriers include saline, artificial cerebrospinal fluid, and other carriers designed for topical or local administration.

[0117] The dose of the viral vector administered to a subject depends primarily on factors such as the clinical condition being treated, the route of administration, and the age, weight, and health status of the subject. For example, the therapeutically effective dose of a viral vector administered to a human subject is generally in the range of 0.1 ml to about 10 ml of a solution containing the viral vector. The therapeutically effective dose is about 1×10 16 , 16 , 12 ~2×10 16 genome copies (GC) of the virus (e.g., about 1×10 1 ~1×10 16 ; about 1×10 3 ~1×10 15 ; about 1×10 3 ~1×10 14 GC, etc.). In some embodiments, 1×10 9 ~1×10 15 genome copies (GC) of the virus are administered per patient. In some embodiments, 1×10 10 ~1×10 16 genome copies (GC) of the virus are administered per patient. In some embodiments, 1×10 12 ~1×10<00000A genome copy (GC) of the virus is administered. In some embodiments, 1 × 10⁶ per patient 12 ~1 × 10 14 A genome copy (GC) of the virus is administered. In some embodiments, 1 × 10⁶ per patient 13 ~1 × 10 14 A genome copy (GC) of the virus is administered. In some embodiments, 1 × 10⁶ per patient 13 ~1 × 10 18 A genome copy (GC) of the virus is administered. In some embodiments, 1 × 10⁶ per patient 13 ~1 × 10 20 A genome copy (GC) of the virus is administered.

[0118] In certain embodiments, the therapeutically effective dose of a viral vector administered to a human subject is generally about 1 × 10⁻⁶. 1 ~2×10 16 Viruses with genome copying (GC) (for example, about 1 × 10⁻⁶) 1 ~1 × 10 16 ; approx. 1×10 3 ~1 × 10 15 ; approx. 1×10 3 ~1 × 10 14 The solution is in the range of approximately 0.1 ml to approximately 10 ml and contains GC (or similar substances).

[0119] Transduction and / or expression of the transgene can be monitored at various time points after administration by DNA, RNA, or protein assays. In some cases, monitoring the expression level of the transgene can be used to determine the frequency and / or dosage of administration. Dosage regimens similar to or lower than those described for therapeutic purposes can be used for immunization. 6.3.2.AAV neutralizing antibodies

[0120] A method provided in this disclosure includes the step of systemically administering a composition comprising at least one antibody or its antigen-binding fragment having the ability to neutralize non-systemically administered rAAV.

[0121] In various embodiments, the non-systemically administered rAAV contains the AAV capsid protein described in Section 5.3.1, and the composition contains at least one antibody or antigen-binding fragment having the ability to neutralize the AAV described in Section 5.3.1.

[0122] In some embodiments, the composition comprises at least one antibody, at least two antibodies, at least three antibodies, at least four antibodies, at least five antibodies, at least six antibodies, at least seven antibodies, at least eight antibodies, at least nine antibodies, or at least ten antibodies. In various embodiments, the composition includes at least 10 antibodies, at least 50 antibodies, at least 100 antibodies, at least 150 antibodies, at least 200 antibodies, at least 250 antibodies, at least 300 antibodies, at least 350 antibodies, at least 400 antibodies, at least 450 antibodies, at least 500 antibodies, at least 750 antibodies, at least 1000 antibodies, at least 1500 antibodies, at least 2000 antibodies, at least 2500 antibodies, at least 3000 antibodies, at least 3500 antibodies, at least 4000 antibodies, at least 4500 antibodies, at least 5000 antibodies, at least 5500 antibodies, at least 6000 antibodies, at least 6500 antibodies, at least 7000 antibodies, at least 7500 antibodies, at least 8000 antibodies, at least 8500 antibodies, at least 9000 antibodies, at least 9500 antibodies, or at least 10,000 antibodies. In various embodiments, the composition includes at least 500 antibodies, at least 1,000 antibodies, at least 5,000 antibodies, at least 10,000 antibodies, at least 15,000 antibodies, at least 20,000 antibodies, at least 25,000 antibodies, at least 30,000 antibodies, at least 35,000 antibodies, at least 40,000 antibodies, at least 45,000 antibodies, at least 50,000 antibodies, at least 55,000 antibodies, at least 60,000 antibodies, at least 65,000 antibodies, or at least 70,000 antibodies.

[0123] In a typical embodiment, the composition contains one polyclonal antibody. In a particular embodiment, the composition contains multiple polyclonal antibodies.

[0124] In some embodiments, the polyclonal antibody is a human antibody. In a typical embodiment, the human antibody is allogeneic to the recipient. In some embodiments, the polyclonal antibody is heterogeneous but is designed to reduce, mitigate, or avoid recognition as a heterogeneous antibody. In certain of these embodiments, the antibody is a humanized antibody.

[0125] In some embodiments, the composition comprises IgG (e.g., IgG1, IgG2, IgG3, IgG4) antibodies. In some embodiments, the composition comprises IgA antibodies.

[0126] In certain embodiments, pooled human plasma-derived immunoglobulins are used. In these embodiments, the immunoglobulins can be pooled from any number of individuals (e.g., donors), including 10 or more individuals, 100 or more individuals, 1000 or more individuals, or more. In certain embodiments, the composition includes a mixture of polyclonal antibodies obtained from at least 100 donors. In a particular embodiment, the composition includes a mixture of polyclonal antibodies obtained from at least 500 donors, at least 1,000 donors, at least 5,000 donors, at least 10,000 donors, at least 15,000 donors, at least 20,000 donors, at least 25,000 donors, at least 30,000 donors, at least 35,000 donors, at least 40,000 donors, at least 45,000 donors, at least 50,000 donors, at least 55,000 donors, at least 60,000 donors, at least 65,000 donors, or at least 70,000 donors.

[0127] In some embodiments, antibodies are isolated or purified from serum before use. Purification can be performed before or after pooling antibodies from different individuals.

[0128] In some embodiments, the pooled immunoglobulins are determined to contain neutralizing antibodies against one or more rAAV capsid serotypes before administration. In some embodiments, the composition contains a pool of immunoglobulins from one or more individuals, which are determined to contain at least one antibody capable of neutralizing AAV of a specific serotype or rAAV containing a specific capsid protein.

[0129] In some embodiments, the polyclonal composition comprises at least one recombinant antibody. In certain embodiments, the composition comprises a mixture of recombinant antibodies. In certain embodiments, the mixture of recombinant antibodies comprises 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more, 100 or more, 1000 or more, 10,000 or more, or 100,000 or more species of recombinant antibodies.

[0130] In some embodiments, a mixture of recombinant polyclonal antibodies comprises antibodies produced from a library of recombinant constructs containing coding sequences for two or more monoclonal antibodies or antigen-binding fragments. In some embodiments, recombinant polyclonal antibodies are produced by mixing and combining antibodies produced from multiple recombinant constructs, each encoding an antibody or antigen-binding fragment. In some embodiments, recombinant polyclonal antibodies recognize and bind to different epitopes of a single antigen. In some embodiments, recombinant polyclonal antibodies recognize and bind to different antigens.

[0131] In certain embodiments, at least one antibody is a monoclonal antibody. In these latter embodiments, the binding specificity of the monoclonal antibody is selected based on its ability to neutralize the administered rAAV.

[0132] In some embodiments, at least one antibody is a monoclonal antibody of a defined subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, or IgA2). When antibody combinations are used, the antibodies may be derived from the same subclass or from different subclasses. For example, the antibody may be an IgG1 antibody. Those skilled in the art can obtain various combinations of different subclasses in different relative ratios.

[0133] In some embodiments, the antibody is a monoclonal antibody against rAAV containing an AAV capsid protein selected from AAV, or AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI.

[0134] In various embodiments, the antibodies are anti-AAV2 antibody; anti-AAV1 antibody; anti-AAV6 antibody; anti-AAV3 antibody; anti-AAV LK03 antibody; anti-AAV7 antibody; anti-AAV8 antibody; anti-AAV hu.37 antibody; anti-AAV rh.10 antibody; anti-AAV9 antibody; anti-AAV hu.68 antibody; anti-AAV10 antibody; anti-AAV5 antibody; anti-AAV3-3 antibody; anti-AAV4-4 antibody; anti-AAV1-A antibody; anti-hu.46-A antibody; anti-hu.48-A antibody; anti-hu.44-A antibody; anti-hu.43-A antibody; anti-AAV6-A antibody; anti-hu.34-B antibody; anti-hu.47-B antibody; anti-hu.29-B antibody; anti-rh.63-B antibody; anti-hu.56-B antibody; anti-hu.45-B antibody; anti-rh.57-B antibody; anti-rh.35-B antibody; anti-rh.58-B antibody; anti-rh.28-B antibody; anti-rh.51-B antibody; anti-rh.19-B antibody; anti-rh.49-B antibody; anti-rh.52-B antibody; anti-rh.13-B antibody; anti-AAV2-B antibody; anti-rh.20-B antibody; anti-rh.24-B antibody; anti-rh.64-B antibody; anti-hu.27-B antibody; anti-hu.21-B antibody; anti-hu.22-B antibody; anti-hu.23-B antibody; anti-hu.7-C antibody; anti-hu.61-C antibody; anti-rh.56-C antibody; anti-hu.9-C antibody; anti-hu.54-C antibody; anti-hu.53-C antibody; anti-hu.60-C antibody; anti-hu.55-C antibody; anti-hu.2-C antibody; anti-hu.1-C antibody; anti-hu.18-C antibody; anti-hu.3-C antibody; anti-hu.25-C antibody; anti-hu.15-C antibody; anti-hu.16-C antibody; anti-hu.11-C antibody; anti-hu.10-C antibody; anti-hu.4-C antibody; anti-rh.54-D antibody; anti-rh.48-D antibody; anti-rh.55-D antibody; anti-rh.62-D antibody; anti-AAV7-D antibody; anti-rh.52-E antibody; anti-rh.51-E antibody; anti-hu.39-E antibody; anti-rh.53-E antibody; anti-hu.37-E antibody; anti-rh.43-E antibody; anti-rh.50-E antibody; anti-rh.49-E antibody; anti-rh.61-E antibody; anti-hu.41-E antibody; anti-rh.64-E antibody; anti-hu.42-E antibody; anti-rh.57-E antibody; anti-rh.40-E antibody; anti-hu.67-E antibody; anti-hu.17-E antibody; anti-hu.6-E antibody; anti-hu.66-E antibody; anti-rh.38-E antibody; anti-hu.32-F antibody; anti-AAV9 / hu antibody; anti-hu.This is a monoclonal antibody selected from the following: 31-F antibody; anti-Anc80 antibody; anti-Anc81 antibody; anti-Anc82 antibody; anti-Anc83 antibody; anti-Anc84 antibody; anti-Anc94 antibody; anti-Anc113 antibody; anti-Anc126 antibody; anti-Anc127 antibody; anti-Anc80L27 antibody; anti-Anc80L59 antibody; anti-Anc80L60 antibody; anti-Anc80L62 antibody; anti-Anc80L65 antibody; anti-Anc80L33 antibody; anti-Anc80L36 antibody; anti-Anc80L44 antibody; anti-Anc80L1 antibody; anti-Anc110 antibody; and anti-Anc80DI antibody.

[0135] In some embodiments, the composition comprises at least one bispecific antibody. In certain embodiments, the bispecific antibody has binding specificity to at least two different epitopes (at least one of which is an rAAV epitope).

[0136] In some embodiments, the antibody is a single-domain antibody (dAb). In some embodiments, the antibody is a diabody (Db). In some embodiments, the antibody is a nanobody. In some embodiments, the antibody is a unibody or a diabody.

[0137] In some embodiments, the antibody is administered in a second pharmaceutical composition. In some embodiments, the second composition comprises a polyclonal antibody purified from human serum or produced from a recombinant construct. 6.3.2.1.IVIG

[0138] In currently preferred embodiments, the composition comprising the neutralizing antibody is intravenous immunoglobulin (IVIG). In certain embodiments, the IVIG is selected from Gammagard® Liquid® (Baxter Healthcare Corporation), Gammagard® S / D, Gammaplex®, Bivigam®, Carimune® NF, Gamunex-C, Gammaked®, Flebogamma® DIF, Octagam®, and Privigen®.

[0139] In some embodiments, recombinant IVIG (rIVIG) generated from a recombinant construct is used. In these embodiments, IVIG is produced in recombinant cells rather than extracted from donor plasma. In these embodiments, primary B cells are collected from thousands of human donors to create a library of constructs or cell lines expressing rIVIG. In some embodiments of the present invention, the library of protein expression constructs is then introduced into a cell population to create a library of engineered cells expressing hundreds, thousands, or millions of antibody proteins. In some embodiments, these antibody proteins are substantially equivalent to antibodies produced by the original primary B cells.

[0140] In some embodiments, massively parallel DNA sequencing is used to determine the diversity of B cells, libraries of protein expression constructs, and / or manipulated host cells. A method for constructing rIVIG can be found in U.S. PreGrant Publication 2016 / 0362470, which is incorporated in its entirety herein by reference.

[0141] In some embodiments, IVIG or rIVIG is administered in a second pharmaceutical composition. 6.3.2.2. AAV Neutralizing Antigen-Binding Fragments

[0142] In some embodiments, the second composition comprises an AAV neutralizing antigen-binding fragment.

[0143] In some embodiments, the second composition comprises a mixture of AAV neutralizing antigen-binding fragments. In certain embodiments, the mixture comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, twenty or more, one hundred or more, one thousand or more, one hundred, ten thousand or more, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred, ten thousand or more, or one hundred thousand, or one hundred thousand, or more one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand, or one hundred thousand

[0144] In a particular embodiment, the antigen-binding fragment is selected from single-chain Fv(scFv), Fab, (Fab')2, and (scFv)2.

[0145] In certain embodiments, the antigen-binding fragment is scFv. In certain embodiments, the antigen-binding fragment is (scFv)2.

[0146] In certain embodiments, the antigen-binding fragment is Fab. In certain embodiments, the antigen-binding fragment is (Fab')2.

[0147] In some embodiments, the antibody or its antigen-binding fragment is administered in a second composition. In some embodiments, the second composition is a second pharmaceutical composition. In certain embodiments, the second pharmaceutical composition comprises an antibody or its antigen-binding fragment having the ability to neutralize non-systemically administered rAAV, and a pharmaceutically acceptable carrier.

[0148] In some embodiments, the second pharmaceutical composition comprises at least 10, at least 100, at least 1,000, at least 10,000, or at least 100,000 antigen-binding fragments. 6.3.3. Route of administration and administration schedule

[0149] This disclosure provides a method comprising administering a first pharmaceutical composition containing rAAV and, as an adjunct, administering a second pharmaceutical composition containing at least one antibody or antigen-binding fragment thereof having the ability to neutralize rAAV. The first pharmaceutical composition containing rAAV is administered non-systemically. The second pharmaceutical composition containing at least one antibody or antigen-binding fragment thereof having the ability to neutralize the non-systemically administered rAAV is administered systemically.

[0150] In some embodiments, a second pharmaceutical composition comprising an antibody or its antigen-binding fragment is administered to the patient before administering a first pharmaceutical composition comprising rAAV.

[0151] In certain embodiments, the second pharmaceutical composition is administered at least 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 22 hours, or at least 24 hours before the administration of the first pharmaceutical composition to the patient. In certain embodiments, the second pharmaceutical composition is administered at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days before the administration of the first pharmaceutical composition to the patient.

[0152] In certain embodiments, the second pharmaceutical composition is administered at least one day, at least one week, or at least two weeks before the administration of the first pharmaceutical composition to the patient. In some embodiments, the second pharmaceutical composition, which contains an antibody or its antigen-binding fragment, is administered after the administration of the first pharmaceutical composition containing rAAV to the patient.

[0153] In certain embodiments, the second pharmaceutical composition is administered at least 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 14 hours, at least 16 hours, at least 18 hours, at least 20 hours, at least 22 hours, or at least 24 hours after the administration of the first pharmaceutical composition to the patient. In certain embodiments, the second pharmaceutical composition is administered 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, or 24 hours after the administration of the first pharmaceutical composition to the patient. In certain embodiments, the second pharmaceutical composition is administered at least 1 day, at least 1 week, at least 2 weeks, or at least 1 month after the administration of the first pharmaceutical composition to the patient. In a particular embodiment, the second pharmaceutical composition is administered at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days after the administration of the first pharmaceutical composition to the patient.

[0154] In some embodiments, a first pharmaceutical composition containing rAAV and a second pharmaceutical composition containing an antibody or its antigen-binding fragment are administered on the same day.

[0155] In some embodiments, a second pharmaceutical composition comprising an antibody or its antigen-binding fragment is administered to a patient in an amount sufficient to alter the distribution of rAAV in the body after administration. Administration of the second pharmaceutical composition reduces rAAV infection in non-target tissues, cells, and / or organs. In certain embodiments, administration of the second pharmaceutical composition reduces rAAV infection in hepatocytes, skeletal muscle cells, cardiomyocytes, lung tissue, or other non-target organ cells other than the non-systemic compartment to which rAAV was administered. In certain embodiments, the second pharmaceutical composition is administered to a patient in an amount sufficient to reduce hepatotoxicity or other non-target organ toxicity of rAAV outside the non-systemic compartment after administration. In certain embodiments, the second pharmaceutical composition is administered in an amount sufficient to reduce toxicity in the dorsal root ganglia (DRG). In some embodiments, the second pharmaceutical composition is administered to a patient in an amount sufficient to reduce systemic toxicity of rAAV after administration.

[0156] In some embodiments, the method further comprises administering a further pharmaceutical composition containing rAAV. In some embodiments, the additional pharmaceutical composition is administered before the administration of the first and second pharmaceutical compositions. In some embodiments, the additional pharmaceutical composition is administered after the administration of the first and second pharmaceutical compositions. In some embodiments, the additional pharmaceutical composition is administered together with a pharmaceutical composition containing at least one antibody or its antigen-binding fragment.

[0157] Accordingly, a method is also provided herein that includes administering a third pharmaceutical composition containing rAAV and, as an adjunct, administering a fourth pharmaceutical composition containing at least one antibody or antigen-binding fragment thereof having the ability to neutralize rAAV. The rAAV in the third pharmaceutical composition may be the same as or different from the rAAV in the first pharmaceutical composition. In some embodiments, the third pharmaceutical composition is identical to the first pharmaceutical composition. In some embodiments, the third pharmaceutical composition is different from the first pharmaceutical composition. In some embodiments, the fourth pharmaceutical composition is identical to the second pharmaceutical composition. In some embodiments, the fourth pharmaceutical composition is different from the second pharmaceutical composition.

[0158] In certain embodiments, a patient who has been administered a first dose of a first pharmaceutical composition containing rAAV may require a second dose (a third dose, a fourth dose, or a fifth or greater dose) of the first pharmaceutical composition to deliver a therapeutically effective amount of rAAV to the patient. In such embodiments, a therapeutically effective amount of the first pharmaceutical composition can be delivered to the patient by administering the second pharmaceutical composition before, simultaneously with (e.g., on the same day) or after the second dose of the first pharmaceutical compound.

[0159] In some embodiments, a second dose of the first pharmaceutical composition is administered to the patient at a lower dose than the first dose of the first pharmaceutical composition administered to the patient. In some embodiments, a second dose of the first pharmaceutical composition is administered to the patient at a higher dose than the first dose of the pharmaceutical composition administered to the patient. In some embodiments, a second dose of the first pharmaceutical composition is administered to the patient at the same dose as the first dose of the pharmaceutical composition administered to the patient.

[0160] In some embodiments, a second dose of the second pharmaceutical composition is administered to the patient at a lower dose than the first dose of the second pharmaceutical composition administered to the patient. In some embodiments, a second dose of the second pharmaceutical composition is administered to the patient at a higher dose than the first dose of the second pharmaceutical composition administered to the patient. In some embodiments, a second dose of the second pharmaceutical composition is administered to the patient at the same dose as the first dose of the second pharmaceutical composition administered to the patient.

[0161] In some embodiments, a first or second dose of the second pharmaceutical composition is administered to the patient before administering a first or second dose of the first pharmaceutical composition (for example, at an exemplary timing as described herein). In some embodiments, a first or second dose of the second pharmaceutical composition is administered to the patient after administering a first or second dose of the first pharmaceutical composition (for example, at an exemplary timing as described herein). In some embodiments, a first or second dose of the first pharmaceutical composition and a second dose of the second pharmaceutical composition are administered to the patient on the same day.

[0162] Furthermore, this specification also provides a method comprising administering a second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or more doses of a first pharmaceutical composition containing rAAV, and supplementing this with a second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or more doses of a second pharmaceutical composition containing at least one antibody or antigen-binding fragment thereof having the ability to neutralize rAAV. 6.3.3.1. Non-systemic administration of rAAV

[0163] As described herein, rAAV or a first pharmaceutical composition comprising rAAV is administered to the patient via a non-systemic route of administration. In some embodiments, rAAV or a composition comprising rAAV is administered to the brain, spinal cord, muscles, eyes, ears, or any other organ by topical or local delivery.

[0164] In some embodiments, rAAV or the first pharmaceutical composition is administered non-systemically to the central nervous system by intrathecal, intraventricular, or intracisional administration. In certain embodiments, rAAV or the first pharmaceutical composition containing rAAV is administered to the brain, spinal cord, retina, olfactory epithelium, eye, or ear. In certain embodiments, the target organ is the brain.

[0165] In certain embodiments, rAAV or the first pharmaceutical composition is administered to target tissue selected from the hippocampus, cortex, thalamus (including the midthalamus), sensory cortex, ventral tegmental area (VTA), prefrontal cortex (PFC), nucleus accumbens (NAc), amygdala, substantia nigra, ventral pallidus, global pallidus, dorsal striatum, ventral striatum, subthalamic nucleus, dentate gyrus, cingulate gyrus, entorhinal cortex, olfactory cortex, primary motor cortex, and cerebellum. In certain embodiments, the target tissue in the brain is selected from the group consisting of the hippocampus, cortex, amygdala, and basal ganglia.

[0166] In certain embodiments, the target organ is the eye.

[0167] In certain embodiments, the target organ is muscle.

[0168] In some embodiments, rAAV or the first pharmaceutical composition is administered topically (e.g., non-systemically). In certain embodiments, rAAV or the first pharmaceutical composition is administered by intrathecal injection or infusion, intraocular injection, intravitreous injection or infusion, inner ear injection or infusion, intraventricular injection or infusion, intracisional injection or infusion (ICM), subretinal injection or infusion, intramuscular injection or infusion, or other non-systemic route of administration. In certain embodiments, the first pharmaceutical composition is administered by intra-articular injection or infusion, intracardiac injection or infusion, intradermal or intradermal injection, or intrathecal injection or infusion.

[0169] In certain embodiments, the first pharmaceutical composition is administered by intrathecal injection.

[0170] In certain embodiments, the first pharmaceutical composition is administered by intraocular injection.

[0171] In certain embodiments, the first pharmaceutical composition is administered by intravitreous injection.

[0172] In certain embodiments, the first pharmaceutical composition is administered by intracerebroventricular injection.

[0173] In certain embodiments, the first pharmaceutical composition is administered by subretinal injection or infusion.

[0174] In certain embodiments, the first pharmaceutical composition is administered by intracisional injection.

[0175] In certain embodiments, the first pharmaceutical composition is administered by inner ear injection.

[0176] In certain embodiments, the first pharmaceutical composition is administered by intramuscular injection. 6.3.3.2. Systemic administration of neutralizing antibodies

[0177] In the methods described herein, the second pharmaceutical composition is administered via a systemic route of administration. In some embodiments, the second pharmaceutical composition is administered by intramuscular injection, intraosseous injection, intratracheal injection, intravenous injection, or subcutaneous injection. In certain embodiments, the systemic route of administration is intravenous injection or infusion. In some embodiments, the systemic route of administration is, but is not limited to, transmucosal, sublingual, or rectal administration.

[0178] The second pharmaceutical composition is administered systemically in this method for the purpose of neutralizing and / or removing rAAVs that have escaped target tissues and organs and are circulating systemically within the patient. For example, rAAVs can escape to systemic compartments including non-target tissues and organs, or to locations within the patient other than the central nervous system.

[0179] In some embodiments, the neutralizing antibody or its fragment is administered in doses ranging from 1 to 2000 mg / kg (patient body weight). In certain embodiments, the neutralizing antibody or its fragment is administered in doses ranging from 1 to 2 mg / kg, 1 to 3 mg / kg, 1 to 5 mg / kg, 1 to 6 mg / kg, 1 to 7 mg / kg, 1 to 8 mg / kg, or 1 to 9 mg / kg (patient body weight). In certain embodiments, the neutralizing antibody or its fragments are administered in doses of at least 1 mg / kg, at least 2 mg / kg, at least 3 mg / kg, at least 4 mg / kg, at least 5 mg / kg, at least 6 mg / kg, at least 7 mg / kg, at least 8 mg / kg, at least 9 mg / kg, at least 10 mg / kg, at least 11 mg / kg, at least 12 mg / kg, at least 13 mg / kg, at least 14 mg / kg, at least 15 mg / kg, at least 16 mg / kg, at least 17 mg / kg, at least 18 mg / kg, at least 19 mg / kg, or at least 20 mg / kg (patient body weight).

[0180] In some embodiments, IVIG is administered in doses ranging from 1 to 2000 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 200 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 100 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 50 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 10 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 2 mg / kg (patient body weight). In some embodiments, IVIG is administered in doses ranging from 1 to 10 mg / ml. In some embodiments, IVIG is administered in doses ranging from 1 to 4 mg / ml.

[0181] In certain applications, the neutralizing antibody or its fragment is administered in doses of at least 20 mg / kg, at least 30 mg / kg, at least 40 mg / kg, at least 50 mg / kg, at least 60 mg / kg, at least 70 mg / kg, at least 80 mg / kg, at least 90 mg / kg, or at least 100 mg / kg (patient body weight). In certain applications, the neutralizing antibody or its fragment is administered in doses of at least 110 mg / kg, at least 125 mg / kg, at least 150 mg / kg, at least 175 mg / kg, at least 200 mg / kg, at least 225 mg / kg, at least 250 mg / kg, at least 275 mg / kg, at least 300 mg / kg, at least 325 mg / kg, at least 350 mg / kg, at least 375 mg / kg, at least 400 mg / kg, at least 425 mg / kg, at least 450 mg / kg, at least 475 mg / kg, at least 500 mg / kg, at least 525 mg / kg, at least 550 It is administered in doses of mg / kg, at least 575 mg / kg, at least 600 mg / kg, at least 625 mg / kg, at least 650 mg / kg, at least 675 mg / kg, at least 700 mg / kg, at least 725 mg / kg, at least 50 mg / kg, at least 775 mg / kg, at least 800 mg / kg, at least 835 mg / kg, at least 850 mg / kg, at least 875 mg / kg, at least 900 mg / kg, at least 925 mg / kg, at least 950 mg / kg, at least 950 mg / kg, at least 975 mg / kg, or at least 1000 mg / kg (patient body weight).

[0182] In a particular embodiment, the neutralizing antibody or its fragment is administered in doses of at least 1100 mg / kg, at least 1200 mg / kg, at least 1300 mg / kg, at least 1400 mg / kg, at least 1500 mg / kg, at least 1600 mg / kg, at least 1700 mg / kg, at least 1800 mg / kg, at least 1900 mg / kg, or at least 2000 mg / kg (patient body weight).

[0183] In some embodiments, the neutralizing antibody or its fragment is administered in doses ranging from 1 to 10 g, 100 mg to 1 g, 1 to 100 mg, 1 to 75 mg, 1 to 50 mg, 1 to 25 mg, 1 to 10 mg, 1 to 5 mg, 1 to 4 mg, or 1 to 2 mg. In some embodiments, the second pharmaceutical composition contains the neutralizing antibody or its fragment in concentrations ranging from 1 to 10 g / ml, 100 mg / ml to 1 g / ml, 1 to 100 mg / ml, 1 to 75 mg / ml, 1 to 50 mg / ml, 1 to 25 mg / ml, 1 to 10 mg / ml, 1 to 5 mg / ml, 1 to 4 mg / ml, or 1 to 2 mg / ml.

[0184] In some embodiments, the second pharmaceutical composition is administered as a single dose. In some embodiments, the second pharmaceutical composition is administered daily. In some embodiments, the second pharmaceutical composition is administered once, twice, three, four, five, six, or seven times a day. In certain embodiments, the second pharmaceutical composition is administered within one week, six days, five days, four days, three days, or two days.

[0185] In a particular embodiment, administration of the second pharmaceutical composition takes at least 1 minute, at least 2 minutes, at least 3 minutes, at least 4 minutes, at least 5 minutes, at least 6 minutes, at least 7 minutes, at least 8 minutes, at least 9 minutes, at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 25 minutes, at least 30 minutes, at least 45 minutes, at least 50 minutes, or at least 60 minutes. In a particular embodiment, administration of the second pharmaceutical composition takes at least 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 45 minutes, 50 minutes, 60 minutes, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, or 120 minutes. 6.3.4. Effective amount of neutralizing antibody

[0186] In preferred embodiments, an effective amount of AAV neutralizing antibody or antigen-binding fragment is administered adjunctly to the patient by systemic administration. The effective amount provided herein refers to an amount sufficient to reduce the distribution of AAV or rAAV in the body outside of the target tissue or organ.

[0187] In some embodiments, the effective dose is sufficient to reduce the detection of AAV or rAAV in the liver, spleen, cervical DRG, lumbar DRG, heart, and / or kidney. In some embodiments, the effective dose is sufficient to reduce the detection of AAV or rAAV in the liver, spleen, and / or heart. In some embodiments, the effective dose is sufficient to reduce the detection of AAV or rAAV in the DRG.

[0188] In some embodiments, the effective dose is sufficient to reduce the level of binding antibodies (BAb) (e.g., IgG and / or IgM) generated against AAV or rAAV in cerebrospinal fluid (CSF) compared to the level in serum. In some embodiments, the effective dose is sufficient to reduce the level of IgM and / or IgG antibodies generated against AAV or rAAV in CSF compared to the level in serum.

[0189] The in vivo distribution of rAAV can be tested in experimental animals by measuring the presence of the rAAV genome, rAAV infection, or the expression of expressible polynucleotides. In some embodiments, targeting is measured in non-human primates (NHPs), mice, rats, birds, rabbits, guinea pigs, hamsters, farm animals (including pigs and sheep), dogs, or cats.

[0190] In some embodiments, specific and nonspecific targeting of rAAV to tissues or organs can be measured after non-systemic administration of rAAV and / or after non-systemic administration of rAAV and systemic administration of a neutralizing antibody or its antigen-binding fragment. In some embodiments, rAAV targeting is measured after non-systemic administration of rAAV and after systemic administration of an antibody or antigen-binding fragment capable of neutralizing rAAV. 6.4. Kit

[0191] In one embodiment, the present disclosure provides a kit for combination therapy comprising a first pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV) as described herein; and a second pharmaceutical composition comprising an AAV neutralizing antibody or an antigen-binding fragment thereof as described herein.

[0192] In some embodiments, the antibody or its antigen-binding fragment binds to the rAAV capsid protein as described in Section 5.3.1.

[0193] In some embodiments, the antibody or its antigen-binding fragment is IgG.

[0194] In some embodiments, the second pharmaceutical composition has the ability to neutralize rAAV. In certain embodiments, the second pharmaceutical composition is AAV2;AAV1;AAV6;AAV3;AAV LK03;AAV7;AAV8;AAV hu.37;AAV rh.10;AAV9;AAV hu.68;AAV10;AAV5;AAV3-3;AAV4-4;AAV1-A;hu.46-A;hu.48-A;hu.44-A;hu.43-A;AAV6-A;hu.34-B;hu.47-B;hu.29-B;r h.63-B;hu.56-B;hu.45-B;rh.57-B;rh.35-B;rh.58-B;rh.28-B;rh.51-B;rh.19-B;rh.49-B;rh.52-B;rh.13-B;AAV2-B;r h.20-B;rh.24-B;rh.64-B;hu.27-B;hu.21-B;hu.22-B;hu.23-B;hu.7-C;hu.61-C;rh.56-C;hu.9-C;hu.54-C;hu.53-C;h u.60-C;hu.55-C;hu.2-C;hu.1-C;hu.18-C;hu.3-C;hu.25-C;hu.15-C;hu.16-C;hu.11-C;hu.10-C;hu.4-C;rh.54-D;rh.4 8-D;rh.55-D;rh.62-D;AAV7-D;rh.52-E;rh.51-E;hu.39-E;rh.53-E;hu.37-E;rh.43-E;rh.50-E;rh.49-E;rh.61-E;hu. 41-E;rh.64-E;hu.42-E;rh.57-E;rh.40-E;hu.67-E;hu.17-E;hu.6-E;hu.66-E;rh.38-E;hu.32-F;AAV9 / hu;hu.31-F;Anc It has the ability to neutralize AAV or rAAV containing the capsid protein of AAV selected from 80;Anc81;Anc82;Anc83;Anc84;Anc94;Anc113;Anc126;Anc127;Anc80L27;Anc80L59;Anc80L60;Anc80L62;Anc80L65;Anc80L33;Anc80L36;Anc80L44;Anc80L1;Anc110; and Anc80DI or its variant forms.

[0195] In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 100 donors. In some embodiments, the second pharmaceutical composition comprises polyclonal antibodies obtained from at least 500, at least 1,000, at least 5,000, or at least 10,000 donors.

[0196] In some embodiments, the second pharmaceutical composition comprises intravenous immunoglobulin (IVIG). In some embodiments, the second pharmaceutical composition comprises recombinant intravenous immunoglobulin (rIVIG). In certain embodiments, the IVIG is selected from Gammagard® Liquid® (Baxter Health Care Corporation), Gammagard® S / D, Gammaplex®, Bivigam®, Carimune® NF, Gamunex-C, Gammaked®, Flebogamma® DIF, Octagam®, and Privigen®.

[0197] In some embodiments, the second pharmaceutical composition includes a recombinant polyclonal antibody.

[0198] In some embodiments, the second pharmaceutical composition comprises an AAV neutralizing antigen-binding fragment selected from single-chain Fv(scFv), Fab, (Fab”)2, and (scFv)2. In some embodiments, the second pharmaceutical composition comprises a bispecific antibody, a single-domain antibody (dAb), a diabody (Db), a nanobody, a unibody, and a diabody.

[0199] In some embodiments, rAAV has the AAV capsid protein described in Section 5.3.1. [Examples]

[0200] 6.5. Examples The following examples are provided as illustrations, not as limitations. 6.5.1. Example 1: Adjunctive administration of IVIG with non-systemic administration of rAAV

[0201] This experiment was conducted to test the hypothesis that systemic administration of IVIG limits the in vivo distribution of ICV-administered AAV9.CAG.GFP. Specifically, the experiment was designed to evaluate whether administering IVIG before ICV administration of AAV9.CAG.GFP limits the transmission of the AAV vector from the CNS to peripheral organs such as the liver, heart, and kidneys. After ICV administration of AAV, the vector is often found in peripheral organs such as the liver, as well as in the DRG. How the vector escapes from the CNS is unknown. IVIG is a purified mixture of IgG obtained from thousands of healthy donors and contains neutralizing antibodies against many AAV serotypes, including AAV9. The hypothesis was that systemic administration of IVIG before ICV administration of AAV9.CAG.GFP neutralizes the vector escaping from the CNS and prevents transduction to peripheral organs such as the liver. As shown below, this experiment demonstrated that IVIG administration limits the transmission of the vector from the CNS to peripheral organs. 6.5.1.1. Experimental Design

[0202] The mice to be treated were divided into five treatment groups (Groups 1-5). Group 1 received ICV-mediated saline injection and served as a vehicle control. Group 2 received AAV9.CAG.GFP via ICV injection. Group 3 received 20 mg of IVIG (10 mg of IVIG / mL of blood) via IV injection two hours before ICV injection of AAV9.CAG.GFP. Group 4 received 20 mg of IVIG via IV injection 24 hours before ICV injection of AAV9.CAG.GFP. Group 5 received the same dose of AAV9.CAG.GFP via IV injection as a control for vector transduction of peripheral organs. Table 1 provides an overview of the experimental design, including the experimental conditions for Groups 1-5. [Table 1]

[0203] Tissue was collected at autopsy (day 14) to evaluate the in vivo distribution of the vector (AAV genomic DNA) and eGFP expression (eGFP mRNA). Furthermore, blood was collected prior to vector administration (day 0) and IVIG administration was verified by a neutralizing antibody (NAb) titer assay. Blood and CSF were also collected at autopsy. Immediately after collection, the tissue was placed in the RNAlater preservation solution, then the RNAlater was removed, and the tissue was rapidly frozen or placed in a lysis buffer containing proteinase K for DNA isolation. Further tissue material was fixed from the same tissue, sectioned, and embedded for anti-GFP staining by immunohistochemistry (IHC). 6.5.1.2. Analysis of Neutralizing Antibody Titer

[0204] Neutralizing antibody (NAb) titer analysis was performed on serum derived from research animals using an in vitro NAb assay. The AAV NAb assay was performed by the immunology core of the Gene Therapy Program at the University of Pennsylvania, as previously described (Calcedo et al., Human Gene Ther Methods. 2018 Apr;29(2):86-95, the entire report is incorporated herein by reference).

[0205] As shown in Table 1, the mice did not have pre-existing antibodies against AAV and were seronegative before study registration. Serum samples were collected before vector administration on the day of vector administration (day 1, or 2 hours or 24 hours after IVIG administration in the applicable groups) and NAb levels were evaluated. NAb titers are shown in Table 2. Animals administered with IVIG, animal IDs #7 to #16, showed similar NAb titers to the IVIG control (fresh IVIG samples not administered to animals). As expected, the NAb titers of animals not administered with IVIG were below the detection threshold. [Table 2] 1 Sample types MR-18-7 to MR-18-16 and IVIG (bottom two rows) showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response. 2 The values ​​represent serum reverse dilutions in which the relative luminescence units (RLU) decreased by 50% compared to the virus control well (no test sample). The detection limit is 1 / 5 dilution. * The detection limit is 1 / 10 dilution - there is not enough serum available at 1 / 5 dilution. ** The detection limit is 1 / 40 dilution - there is not enough serum available at 1 / 5 dilution. 6.5.1.3. Analysis of Conjugated Antibody Titer

[0206] Mouse B-cell responses were evaluated in serum and CSF using in vitro conjugated antibody (BAb) ELISA. BAb titer analysis was performed on serum and cerebrospinal fluid from study animals using an in vitro BAb ELISA assay on day 14 (necropsy). AAV9 BAb testing was performed using anti-mouse IgM-HRP (Invitrogen, catalog number 31456) or anti-mouse IgG-HRP (Promega, catalog number W402B), as previously described (Calcedo et al., Human Gene Ther Methods. 2018 Apr;29(2):86~95). Groups were pooled for analysis of IgG in serum and CSF.

[0207] Table 3 shows the IgM BAb titers for each animal. [Table 3]

[0208] Table 4 shows the IgG BAb titers from the pooled groups. [Table 4]

[0209] As shown in Tables 3 and 4, mice treated with IVIG before AAV administration expressed lower levels of IgM and / or IgG antibodies against AAV in the CSF compared to serum IgM and / or IgG antibody levels. This suggests that IVIG protects the CNS from the expression of high levels of IgM and / or IgG antibodies against the administered AAV capsid. 6.5.1.4. Distribution of vector genomes in the body

[0210] The vector genome distribution (i.e., AAV vector genome DNA) in various tissues was measured by ddPCR and expressed as the ratio of eGFP DNA copy number to RPP30 DNA copy number (eGFP / RPP30), a rough indicator of vector genome copies per cell. Tissues were collected 14 days after AAV9.CAG.GFP injection, and DNA was isolated. DNA was analyzed using Bio-Rad ddPCR Supermix for Probes (without dUTP) (Bio-Rad 1863024) in combination with primers and probes specific to the DNA encoding the eGFP transgene and the DNA encoding the non-human primate RPP30 reference. The primers and probes were designed to include intron sequences to prevent contamination RNA from interfering with the accurate quantification of the vector genome. After thermal cycling, samples were analyzed using the Absolute Quantitation program on a Bio-Rad QX200 Droplet Reader instrument.

[0211] The results of the in vivo distribution measurements of the vector genome are shown in Figures 1A (brain), 2B (liver), 2C (spleen), 2D (cervical DRG), 2E (lumbar DRG), 2F (heart), and 2G (kidney). For example, the copy (cp) / μL amount of DNA encoding the eGFP transgene was normalized to the cp / μL amount of DNA encoding the RPP30 reference, and multiplied by 100 to generate the ratio of the copy number of eGFP DNA to the copy number of RPP30 DNA. For each tissue, results from three biological replicates are provided for each treatment. Statistical significance was determined by one-way ANOVA using p-values ​​and is indicated by asterisks. * P<0.05, ** p<0.002; *** P<0.001; **** p<0.0001, ns = not significant.

[0212] Figure 1A shows the ratio of eGFP and RPP30 DNA copy numbers in the brain. No significant differences were observed between any of the treatment groups.

[0213] Figure 1B shows the ratio of eGFP to RPP30 DNA copy numbers in the liver. Administration of IVIG 2 hours or 24 hours prior to AAV9.CAG.GFP ICV administration reduced vector transduction.

[0214] Figure 1C shows the ratio of DNA copy numbers of eGFP and RPP30 in the spleen. Animals administered AAV9 via tail vein IV injection had similar vector genome copies compared to ICV-injected controls. This suggests that the vector escapes from the CNS into circulation. Animals administered IVIG 2 hours before AAV9.CAG.GFP ICV administration showed a significant increase in the vector genome, while the group administered IVIG 24 hours before AAV9.CAG.GFP ICV administration showed an increase in the vector genome, but not a significant increase. This is likely due to the clearance or degradation of some circulating IVIG prior to vector administration during the 24-hour treatment. This result is expected as the antibody-bound capsid is a target for phagocytosis by circulating phagocytic cells. Therefore, this increase in the vector genome in the spleen may indicate that the AAV vector was inactivated in the macrophage, neutrophil, and dendritic cell populations present in the spleen at the time of necropsy (day 14).

[0215] Figures 1D-1E show the copy number ratios of eGFP and RPP30 DNA in cervical DRG (Figure 1D) and lumbar DRG (Figure 1E).

[0216] Figure 1F shows the ratio of DNA copy numbers for eGFP and RPP30 in the heart. Animals administered AAV9.CAG.GFP via ICV or IV injection showed similar vector transduction in the cardiomyocyte. Animals administered IVIG 2 hours or 24 hours prior to AAV9.CAG.GFP ICV administration showed reduced vector transduction in the heart (i.e., reduced vector genome copies per cell), which was statistically significant at 24 hours.

[0217] Figure 1G shows the ratio of DNA copy numbers for eGFP and RPP30 in the kidney. Animals administered AAV9.CAG.GFP via ICV or IV showed similar vector transduction. Animals administered IVIG 2 hours or 24 hours prior to AAV9.CAG.GFP ICV administration showed significantly reduced vector transduction in the kidney (i.e., fewer vector genome copies per cell). 6.5.1.5. Gene Expression

[0218] eGFP mRNA expression in various tissues was measured by RT-ddPCR and expressed as the ratio of eGFP transcript to RPP30 transcript (eGFP / RPP30), a rough indicator of eGFP mRNA copies per cell. Tissues were collected 14 days after injection, and RNA was isolated. RNA from the samples was analyzed using the Bio-Rad One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad1864022) in combination with primers and probes specific to the eGFP transgene and the non-human primate RPP30 reference gene. Reverse primers for both targets acted as reverse transcription primers for the reverse transcription step. Where possible, primers and probes were designed to cross exon-exon junctions to prevent cross-reactivity with contaminating DNA. After thermal cycling, samples were analyzed using the Absolute Quantitation program on a QX200 Droplet Reader instrument.

[0219] The results of eGFP mRNA expression measurements are shown in Figures 2A (brain), 2B (liver), 2C (spleen), 2D (cervical / thoracic DRG), 2E (lumbar DRG), 2F (heart), and 2G (kidney). For example, the cp / μL amount for the eGFP transgene was normalized to the cp / μL amount for the RPP30 reference gene and multiplied by 100 to generate the ratio of eGFP transcript to RPP30 transcript (eGFP / RPP30). For each tissue, results from three biological replicates are provided for each condition. Statistical significance was determined by one-way ANOVA using p-values ​​and is indicated by asterisks. * P<0.05, ** p<0.002; *** P<0.001; **** p<0.0001, ns = not significant.

[0220] Figure 2A shows the ratio of eGFP transcript to RPP30 transcript in the brain. Animals treated with IVIG showed no difference in eGFP mRNA expression compared to animals administered AAV9.CAG.GFP via ICV administration.

[0221] Figure 2B shows the ratio of eGFP transcript to RPP30 transcript in the liver. Animals administered AAV9.CAG.GFP via ICV showed similar levels of eGFP mRNA expression as animals administered AAV9.CAG.GFP via IV tail vein injection. Animals administered IVIG 2 hours or 24 hours before ICV administration of AAV9.CAG.GFP showed a significant decrease in eGFP mRNA expression. This expression data is consistent with the in vivo distribution data of the vector genome.

[0222] Figure 2C shows the ratio of eGFP transcript to RPP30 transcript in the spleen. Animals administered AAV9.CAG.GFP via ICV showed reduced GFP expression compared to animals administered AAV9.CAG.GFP via IV. Animals administered IVIG 2 hours or 24 hours before ICV administration of AAV9.CAG.GFP showed a slight decrease in GFP expression compared to the ICV monotherapy group, but this decrease was not statistically significant.

[0223] Figures 2D-2E show the ratio of eGFP transcript to RPP30 transcript in the cervical / thoracic DRG (Figure 2D) and lumbar DRG (Figure 2E). In both the cervical / thoracic DRG and lumbar DRG groups, animals administered AAV9.CAG.GFP via ICV showed no difference in eGFP mRNA expression compared to animals treated with IVIG before ICV administration of AAV9.CAG.GFP. Animals administered AAV9.CAG.GFP via ICV showed a slight increase in GFP expression compared to animals administered AAV9.CAG.GFP via IV (however, this was not statistically significant).

[0224] Figure 2F shows the ratio of eGFP transcript to RPP30 transcript in the heart. Animals administered IVIG 2 hours or 24 hours before ICV administration of AAV9.CAG.GFP showed decreased GFP expression, but this was not statistically significant.

[0225] Figure 2G shows the ratio of eGFP transcript to RPP30 transcript in the kidney. Animals administered IVIG 2 hours or 24 hours before ICV administration of AAV9.CAG.GFP showed a significant decrease in GFP expression. 6.5.1.6. Protein Expression

[0226] Tissue samples for IHC analysis were collected 14 days after vector administration and immediately immersed in 10% neutral buffered formalin for approximately 48 hours, then transferred to 70% ethanol. The samples in ethanol were transported at ambient temperature to Histoserv (Germantown, Maryland). Briefly, the tissue samples were trimmed and embedded in paraffin. The resulting blocks were sectioned by microtome, mounted on glass slides, and stained to detect GFP. Briefly, the slides were calcined at 55-65°C for 15 minutes to remove the paraffin and stained with GeneTex, GTX20290 GFP antibody and anti-rabbit HRP-labeled secondary antibody (Biocare Medical, BRR4009) in a 1:1,000 dilution of Monet Blue. Betazoid DAB (Biocare Medical, BDB2004) was used for development, and Meyer's hematoxylin (StatLab, HXMMHPT) was used for counterstaining. Representative images from each condition (i.e., saline; AAV9.CAG.GFP ICV; AAV9.CAG.GFP ICV with 2 hours of IVIG; AAV9.CAG.GFP with 24 hours of IVIG; or AAV9.CAG.GFP IV) are shown in Figure 3A (brain), 3B (liver), 3C (spleen), 3D (cervical / thoracic DRG), 3E (lumbar DRG), 3F (heart), and 3G (kidneys).

[0227] Figure 3A shows representative images of brain sections obtained after anti-GFP IHC. As expected, Figure 3A shows eGFP expression in the brains of ICV-administered animals. eGFP expression was little to no in brains administered via IV injection, and there was no background in the saline control. Table 5 shows GFP for each animal. + Provides a summary of the proportion of brain cells. [Table 5-1] [Table 5-2] *MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response.

[0228] Figure 3B shows representative images of liver cross-sections obtained after anti-GFP IHC. GFP expression was evident in the group administered AAV alone, either by ICV or IV injection. In animals administered IVIG 2 or 24 hours before ICV administration, GFP expression was not detected in the liver, similar to controls injected with saline. One exception was animal #15 in the 24-hour IVIG treatment group, which had very few GFP-positive cells (see Table 6). This animal also had higher levels of GFP expression compared to other animals in the group, as measured by RT-ddPCR. Table 6 shows the GFP expression of each animal. + This provides a summary of the percentage of hepatocytes. [Table 6] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response.

[0229] Figure 3C shows representative images of spleen sections obtained after anti-GFP IHC. No difference in GFP expression was detected between any of the treatment groups. Due to the nature of the spleen, animals injected with saline have a high level of background. Table 7 shows GFP expression for each animal. + This provides a summary of the proportion of spleen cells. [Table 7] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response.

[0230] Figures 3D-3E show representative images of cervical / thoracic DRG sections (Figure 3D) and lumbar DRG sections (Figure 3E) obtained after anti-GFP IHC. Tables 8 and 9 show GFP in cervical / thoracic DRG (Table 8) and lumbar DRG (Table 9). + Provides a summary of cell proportions. [Table 8-1] [Table 8-2] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response. [Table 9] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response.

[0231] Figure 3F shows representative images of cardiac sections obtained after anti-GFP IHC. GFP expression was observed in the hearts of groups treated with AAV9.CAG.GFP by either ICV or IV administration. In animals administered IVIG 2 or 24 hours prior to AAV9.CAG.GFP ICV administration, GFP expression was not detected in the heart and was similar to that of controls injected with physiological saline. Table 10 shows the GFP expression of each animal. + Provides a summary of the proportion of cardiac cells. [Table 10] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response.

[0232] Figure 3G shows representative images of kidney sections obtained after anti-GFP IHC. GFP expression was observed in the kidneys of groups treated with AAV9.CAG.GFP by either ICV or IV administration. GFP expression was limited to tubules adjacent to the glomeruli, suggesting specific expression in epithelial cells representing the macula densa. In animals administered IVIG 2 or 24 hours prior to AAV9.CAG.GFP ICV administration, GFP expression was not detected in the kidneys, similar to controls injected with physiological saline. Table 11 shows the GFP expression for each animal. + Provides a summary of the percentage of kidney cells. [Table 11-1] [Table 11-2] * MR-18-7 to MR-18-16 showed a positive NAb response, while MR-18-2 to MR-18-6 and MR-18-17 to MR-18-19 showed a negative NAb response. 6.5.1.7. Conclusion

[0233] This experiment was designed to test the hypothesis that systemic administration of IVIG before ICV administration of AAV9.CAG.GFP limits the transduction of peripheral organs by AAV9.CAG.GFP that escapes the central nervous system (CNS).

[0234] The vector genome was observed in the livers, hearts, and kidneys of the groups treated with AAV9.CAG.GFP by either ICV or IV administration. The presence of the vector genome in peripheral organs suggests that AAV is proficient at escaping from the CNS after ICV injection. Animals treated with IVIG prior to ICV administration of AAV showed a significant decrease in transduction and expression in the liver, heart, and kidney compared to animals administered only ICV. The spleen showed an increase in the vector genome in animals pretreated with IVIG, which may be due to phagocytosis of antibody-bound capsids by circulating phagocytes rather than true transduction. Consistent with this, GFP expression data (IHC or RT-ddPCR) showed no significant change between the group administered IVIG and the group administered AAV without IVIG. Overall, IVIG administration prior to AAV ICV administration restricted AAV transduction in peripheral tissues, including the liver, heart, and kidney. 7. Incorporation by Reference

[0235] All publications, patents, patent applications, and other documents cited in this application are hereby incorporated by reference in their entirety for all purposes as if each individual publication, patent, patent application, or other document were specifically and individually indicated to be incorporated by reference for all purposes. 8. Equivalents

[0236] Although various specific embodiments have been illustrated and described, the above specification is not limiting. It will be understood that various changes can be made without departing from the spirit and scope of the invention. Upon review of this specification, many variations will be apparent to those skilled in the art.

Chem.

Chem.

Chem.

Chem.

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. A composition for use in a method of treating a patient by non-systemic administration of a recombinant adeno-associated virus (rAAV) to a target site, said composition comprising at least one antibody capable of neutralizing said non-systemically administered rAAV, and an improvement comprising adjunctively administering to said patient by systemic administration said composition comprising at least one antibody capable of neutralizing said non-systemically administered rAAV.

2. The composition for use of claim 1 , wherein the at least one antibody binds to at least one capsid protein of the rAAV.

3. Read more 2003; rh.100;2269;226 hu.688; 2644-4;2261-2; 8-A;hu\44-A; ;hu.34-3; rh.63-B{hu555B; 5.580.358.38.

58. 280000000000000000 93000000000000 ;rh.2003; hu.27_3; u.23-3; 44.53; ;;hu\.600_3; 10.1800; 5.15.16.111 100000000; rh.448.44; A67m;;rh;urE;rh(51m;;hu. 39-55; 50000000000000000000 ;hu.411-5;rh.644-5; ;rh555;rh(40-; u.17-5; 34-5;100.2269:21.31 -F;Anc80;;nc81;;nc82;;ncx 3.2813;2113; 261277;2778 9.2006.2028.2000 256;23368281882 4444; 80000000000000000 The 1,000,000,000,000,000,000,000,000,000,000,000,000,000,000 people, 【4】 The composition according to any one of claims 1 to 3 for use having the ability to neutralize rAAV selected from AAV2; AAV1; AAV6; AAV3; AAV LK03; AAV7; AAV8; AAV hu.37; AAV rh.10; AAV9; AAV hu.68; AAV10; AAV5; AAV3-3; AAV4-4; AAV1-A; hu.46-A; hu.48-A; hu.44-A; hu.43-A; AAV6-A; hu.34-B; hu.47-B; hu.29-B; rh.63-B; hu.56-B; hu.45-B; rh.57-B; rh.35-B; rh.58-B; rh.28-B; rh.51-B; rh.19-B; rh.49-B; rh.52-B; rh.13-B; AAV2-B; rh.20-B; rh.24-B; rh.64-B; hu.27-B; hu.21-B; hu.22-B; hu.23-B; hu.7-C; hu.61-C; rh.56-C; hu.9-C; hu.54-C; hu.53-C; hu.60-C; hu.55-C; hu.2-C; hu.1-C; hu.18-C; hu.3-C; hu.25-C; hu.15-C; hu.16-C; hu.11-C; hu.10-C; hu.4-C; rh.54-D; rh.48-D; rh.55-D; rh.62-D; AAV7-D; rh.52-E; rh.51-E; hu.39-E; rh.53-E; hu.37-E; rh.43-E; rh.50-E; rh.49-E; rh.61-E; hu.41-E; rh.64-E; hu.42-E; rh.57-E; rh.40-E; hu.67-E; hu.17-E; hu.6-E; hu.66-E; rh.38-E; hu.32-F; AAV9 / hu; hu.31-F; Anc80; Anc81; Anc82; Anc83; Anc84; Anc94; Anc113; Anc126; Anc127; Anc80L27; Anc80L59; Anc80L60; Anc80L62; Anc80L65; Anc80L33; Anc80L36; Anc80L44; Anc80L1; Anc110; and Anc80DI.

5. The composition for use according to any one of claims 1 to 4, wherein said composition comprises a monoclonal antibody or a polyclonal antibody comprising a mixture of monoclonal antibodies.

6. The composition for use according to any one of claims 1 to 5, wherein said composition comprises polyclonal antibodies obtained from at least 100 donors.

7. The composition for use according to any one of claims 1 to 6, wherein the composition is intravenous immunoglobulin (IVIG).

8. The composition for use according to any one of claims 1 to 7, characterized in that said composition is administered by intravenous injection or infusion.

9. The composition for use according to any one of claims 1 to 8, characterized in that said composition is IVIG, and said IVIG is administered in a dose ranging from 1 to 2000 mg / kg (patient body weight).

10. The composition for use according to claim 9, characterized in that the IVIG is administered in a dose ranging from 1 to 10 mg / ml.

11. 10. The composition for use according to claim 9, characterized in that IVIG is administered as a single dose.

12. The composition for use according to any one of claims 1 to 11, characterized in that the IVIG is administered daily, twice a day, three times a day, or four times a day.

13. 13. The composition for use according to any one of claims 1 to 12, wherein the composition is administered prior to administration of the rAAV to the patient, optionally at least 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, or at least 24 hours before administration of the rAAV to the patient.

14. 14. The composition for use according to any one of claims 1 to 13, wherein the composition is administered after administration of the rAAV to the patient, and optionally, the composition is administered within 30 minutes, at least 1 hour, at least 2 hours, at least 4 hours, at least 6 hours, at least 24 hours, or within 1 week after administration of the rAAV to the patient.

15. The composition for use according to any one of claims 1 to 14, characterized in that the composition is administered on the same day that the rAAV is administered to the patient.

16. The composition for use according to any one of claims 1 to 15, characterized in that the composition is administered in an amount sufficient to alter the biodistribution of the rAAV after administration to the patient.

17. The composition for use according to claim 16, which reduces infection of hepatocytes by altering the biodistribution of rAAV.

18. The composition for use according to claim 16, which reduces infection of cells other than the target site by altering the distribution of rAAV in the body.

19. The composition for use according to any one of claims 1 to 18, characterized in that the composition is administered in an amount sufficient to reduce hepatotoxicity of the rAAV after administration to the patient.

20. The composition for use according to any one of claims 1 to 19, characterized in that the composition is administered in an amount sufficient to neutralize rAAV released from the target site.

21. The composition for use according to any one of claims 1 to 20, wherein the target site is selected from the brain, spinal cord, muscle, eye and ear of the patient.

22. A first pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV), non-systemically administering to a target site in a patient said first pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV); adjunctively administering to said patient by systemic administration a second pharmaceutical composition comprising at least one antibody capable of neutralizing said non-systemically administered rAAV; 20. A method for treating a patient comprising administering to said patient a first pharmaceutical composition comprising administering to said patient a first

23. 1. A kit for combination therapy comprising a first pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV) and a second pharmaceutical composition comprising at least one antibody capable of neutralizing the rAAV of the first pharmaceutical composition when administered non-systemically.